Medigene AG announced the expansion of the senior management team by appointing Dr. Dr. Olav Zilian as Senior Vice President Corporate Development, Dr. Kai Pinkernell as Senior Vice President/Chief Medical Officer (CMO) and Dr. Markus Dangl as Senior Vice President Research & Pre-Clinical Development.
Market Closed -
Other stock markets
|
After market 01:23:47 pm | |||
1.255 EUR | -1.57% |
|
1.245 | -0.80% |
May. 21 | Medigene, BioNTech Extend Cancer Immunotherapy Partnership | MT |
May. 21 | Medigene AG's Global Research & Collaboration Agreement with BioNTech SE to Extend Beyond Initial Announced Term | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.70% | 40.2M | |
+17.24% | 124B | |
+18.98% | 112B | |
+3.52% | 22.94B | |
-11.52% | 17.02B | |
-16.50% | 16.88B | |
-39.57% | 16.87B | |
+3.77% | 13.63B | |
+23.84% | 11.61B | |
+108.32% | 10.31B |
- Stock Market
- Equities
- MDG1 Stock
- News Medigene AG
- Medigene AG Announces Management Changes